Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report
Frontiers in Oncology · 16.03.2026 · 16
DOI: 10.3389/fonc.2026.1771103 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 16.03.2026. Verfasst von David A Martinez-Gamboa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), is a rare subset of primary cutaneous lymphoma known for its aggressive behavior, poor prognosis, and limited treatment options, particularly in the relapsed or refractory setting. We report a case of a patient diagnosed with PCDLBCL-LT who achieved a clinically significant response and sustained remission for seven months with acalabrutinib, a covalent inhibitor of Bruton’s tyrosine kinase (BTK), before disease progression. Case presentation An 88-year-old woman presented with a rapidly enlarging ulcerated lesion on the left lower leg. Histopathological and immunohistochemical analyses confirmed the diagnosis of PCDLBCL-LT. She was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy, followed by external beam radiation therapy (RT). These interventions resulted in only a partial response, and the disease progressed within several months. The patient was receiving direct oral anticoagulant (DOAC) therapy for left lower limb deep vein thrombosis, and she also had a history of hypertension. Considering the increased risk of major bleeding associated with DOAC use and the elevated risk of cardiovascular adverse events previously reported with ibrutinib, an alternative BTK inhibitor was considered. Accordingly, she was initiated on acalabrutinib at a dose of 100 mg orally twice daily. The patient exhibited a rapid and robust clinical response, with complete resolution of cutaneous lesions and sustained remission lasting seven months. Ultimately, the disease progressed, and given her advanced age and overall poor performance status, she was transitioned to hospice care. She subsequently died 14 months after initiating acalabrutinib.
Conclusion
This report documents the first known case of successful treatment of relapsed/refractory PCDLBCL-LT with acalabrutinib. Despite advanced age and poor performance status, the patient experienced rapid symptom resolution and durable remission without treatment-related adverse events. These findings suggest that BTK inhibitors may represent a promising therapeutic approach for PCDLBCL-LT, either as monotherapy or in combination with anti-CD20 antibodies. Further investigation into novel targeted therapies is urgently needed for this rare and aggressive lymphoma subtype.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United States.
- Cancer Research and Cellular Therapies Laboratory, Mayo Clinic, Phoenix, AZ, United States.
- Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, United States.
- Department of Dermatology, Mayo Clinic, Phoenix, AZ, United States.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, United States.
Zitieren
APA
Martinez-Gamboa, D. A., Beas, F. F., Moreno-Cortes, E., Swanson, L. A., Mangold, A. R., Vargas, F., & Castro, J. E. (2026). Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1771103
Vancouver
Martinez-Gamboa DA, Beas FF, Moreno-Cortes E, Swanson LA, Mangold AR, Vargas F, et al. Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1771103
BibTeX
@article{MartinezGamboa2026,
author = {Martinez-Gamboa, David A and Beas, Flavio F and Moreno-Cortes, Eider and Swanson, Leah A and Mangold, Aaron R and Vargas, Fabio and Castro, Januario E},
title = {Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1771103}
}
EUVIMED